The Swedish BioFINDER 2 Study
A legfontosabb adatok
- Ki végzi
- Skane University Hospital
- Hol
- Malmö (Svédország)A helyszín megnézése
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 2950 fő, tervezett
- Kezdés
- 2017. máj. 15.
- Várható befejezés
- 2036. dec.
- A vizsgálat típusa
- Beavatkozással járó, 5 csoport
- A vizsgált kezelések
- Flutemetamol F18 Injection
- [18F]-RO6958948
- Elecsys (Roche) Abeta42, Ttau and Ptau
- Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
- A regiszteradat frissítve
- 2026. április 6.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan kognitívan egészséges felnőtteket keres, valamint olyan embereket, akiknek memória- vagy gondolkodási problémájuk, Alzheimer-kóros demenciájuk vagy más agyi betegségük van, például Parkinson-kór, frontotemporális demencia vagy Lewy-testes demencia. Svédországi, svédül beszélő emberek vehetnek részt.
- Életkor
- A nyilvántartás összességében 20 évtől 100 évig adja meg a korhatárt. A csoportok: A: 40-65 év, B: 66-100 év, C, D és E: 40-100 év.
- Nem
- Nők és férfiak is részt vehetnek.
- A betegség stádiuma
- Egészséges emberek, akiknek nincs memória- vagy gondolkodási panaszuk (MMSE pontszám 27-30 a 40-65 évesek, 26-30 a 66-100 évesek között). Szubjektív kognitív hanyatlásban vagy enyhe kognitív zavarban szenvedők (MMSE 24-30, nincs demencia). Alzheimer-kór okozta demenciában szenvedők (MMSE 12-26). Más demenciával vagy mozgászavarral járó agyi betegséggel élők: FTD, PDD, DLB, szubkortikális VaD, PD, PSP, MSA, CBS vagy ALS.
- Biomarker vagy leletérték
- A szubjektív kognitív hanyatlásban vagy enyhe kognitív zavarban szenvedőknél a liquorban kóros Aβ42/40 arány szükséges, vagy Parkinson-kór, Lewy-testes betegség, vaszkuláris neurokognitív zavar vagy frontotemporális demencia okozta enyhe kognitív zavar.
A részvétel fő kizáró okai
- Súlyos, instabil betegség vagy szervelégtelenség, ami megnehezíti a részvételt
- Jelenlegi jelentős alkohol- vagy szerhasználat
- Jelentős neurológiai vagy pszichiátriai betegség (az egészséges csoportoknál)
- Lumbálpunkció, MRI vagy PET visszautasítása
- Nem beszél és nem ért svédül tolmács nélkül
A regiszter feltételei, szó szerint
Mind a 42 feltétel megnézéseKevesebb
Ki nem vehet részt
- Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study
- Significant neurological or psychiatric illness
- Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders
- Do not fulfill the criteria for MCI or any dementia according to DSM-V
- Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study
- Significant neurological or psychiatric illness
- Refusing lumbar puncture, MRI or PET; COHORT C: Subjective cognitive decline and mild cognitive impairment INCLUSION CRITERIA
- Do not fulfill the criteria for any dementia (major neurocognitive disorder) according to DSM-V
- The medical doctor (after clinical assessments, cognitive testing, CSF analyses and structural brain imaging) believes the cognitive complaints are caused by an incipient neurocognitive disorder of any sort. This is defined as any case fulfilling the criteria above (i.e. both SCD and MCI) with an abnormal CSF Aβ42/40 ratio, which is strongly associated with brain Aβ pathology and prodromal Alzheimer's disease. Further, cases with MCI (=minor neurocognitive impairment) due to either Parkinson's disease, Lewy body disease, vascular neurocognitive disorder or frontotemporal dementia (please see Appendix below for clinical criteria and references) can also be included
- Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study
- Refusing lumbar puncture, MRI or PET; COHORT D: Dementia due to Alzheimer's disease INCLUSION CRITERIA
- Fulfill the criteria for dementia (major neurocognitive disorder) due to Alzheimer's disease (DSM-V)
- Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study
- Fulfill the criteria for dementia (major neurocognitive disorder) due to FTD, PDD, DLB or subcortical VaD alternatively the criteria for PD, PSP, MSA, CBS or ALS
- Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study
- Refusing lumbar puncture, MRI or PET; COHORT B: Cognitively healthy elderly individuals (66-100 years of age) INCLUSION CRITERIA
- Age 66-100 years
- Age 40-100 years
- Age 40-100 years
- Age 40-100 years
- Current significant alcohol or substance misuse
- MMSE score 26-30 at screening visit
- Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests
- Current significant alcohol or substance misuse
- Referred to the memory clinics due to cognitive symptoms experienced by the patient and/or informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis, psychomotor or social cognitive complaints
- MMSE score of 24 - 30 points
- Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests
- Current significant alcohol or substance misuse
- Referred to the memory clinics due to cognitive symptoms experienced by the patient and/or informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis or psychomotor complaints
- MMSE score of 12-26 points
- Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests
- Current significant alcohol or substance misuse
- Refusing lumbar puncture, MRI or PET; COHORT E: Other dementias INCLUSION CRITERIA
- Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests
- Current significant alcohol or substance misuse
- Refusing lumbar puncture, MRI or PET
Egyéb feltételek
- COHORT A: Cognitively healthy younger individuals (40-65 years of age) INCLUSION CRITERIA
- Age 40-65 years
- Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders
- MMSE score 27-30 at screening visit
- Do not fulfill the criteria for MCI or any dementia according to DSM-V
- Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 20 és 100 év között vagy?
Helyszínek itt: Svédország
- Region SkåneMalmö, SvédországRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in cerebrospinal fluid samples. The BioFINDER 1 study has resulted in more than 40 publications during the last three years, many in high impact journals, and some the of the results have already had important implications for the diagnostic work-up patients with AD in the clinical routine practice.
A teljes eredeti leírásKevesebb
The original BioFINDER 1 cohort started to include participants in 2008. Since then there has been a rapid development of biochemical and neuroimaging technologies which enable novel ways to the study biological processes involved in Alzheimer's disease in living people. There has also been a growing interest in the earliest stages of AD and other neurodegenerative diseases. With the advent of new tau-PET tracers there is now an opportunity to elucidate the role of tau pathology in the pathogenesis of AD and other tauopathies. The Swedish BioFINDER 2 study has been designed to complement the BioFINDER 1 study and to e.g. address issues regarding the role of tau pathology in different dementias and in preclinical stages of different dementia diseases. Further, the clinical assessments and MRI methods have been further optimized compared to BioFINDER 1. Detailed assessments of motor aspects and dual task performance, which is part of a sub-study named Motor-ACT: "Motor aspects and activities in relation to cognitive decline and brain pathologies, has been added to further optimize assessment of motor function.
A vizsgálat 5 csoportja
- COHORT A: Cognitively healthy younger individuals (40-65 y)Egyéb csoport
We will recruit 300 cognitively healthy individuals from the Malmö Offspring study, which is an epidemiological study. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele. FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling. MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline. An auxiliary cohort (termed "Cohort A2") of 40 healthy individuals aged 20-40 years of age will also be included.
Kezelés: Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau és Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
- COHORT B: Cognitively healthy elderly individuals (66-100 y)Egyéb csoport
We will recruit 300 cognitively healthy individuals from the Malmö/Lund region, where we will aim to include as many individuals as possible that did participate in the Malmö Diet and Cancer study during the early 1990's. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE 4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele. FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling. MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline. Motor assessments (Motor-ACT) are performed at baseline and afte
Kezelés: Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau és Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
- COHORT C: SCD and MCIEgyéb csoport
\>750 patients with either subjective cognitive decline (SCD) or mild cognitive impairment (MCI) will be recruited in a consecutive fashion from the Skåne University Hospital and Ängelholm Hospital. We will only include cases where the medical doctor believes that the cognitive symptoms are caused by an incipient neurocognitive disorder. For example, cases with evidence of brain amyloid pathology (i.e. an abnormal CSF Aβ42/40 ratio). FOLLOW-UP FOR 6 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed. CSF/blood sampling, Tau PET, Amyloid PET and MRI will be done every 2 years. Motor assessment (Motor-ACT) at year 1, year 3 and year 5. A auxiliary cohort ("Cohort C2") \>150 cases with SCD/MCI where the doctor does not suspect incipient neurocognitive disorder, will undergo the same baseline investigations, but they will be followed up clinically only after 2, 4 and 8 y. In total, 1000 patients with SCD or MCI will be included.
Kezelés: Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau és Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
- COHORT D: Dementia due to Alzheimer's diseaseEgyéb csoport
400 patients with mild to moderate dementia due to Alzheimer's disease (AD) will be recruited from the Skåne University Hospital and Ängelholm Hospital in southern Sweden. We will include at least 50 cases aged 40-65 years of age, at least 200 cases aged 66-79 years of age and at least 50 cases aged 80-100 years of age. FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed. CSF/blood sampling, Tau PET and MRI will be done at baseline and after 2 years. Amyloid PET is performed at baseline for a subset of this group.
Kezelés: [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau és Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
- COHORT E: Other dementiasEgyéb csoport
Patients with primary neurodegenerative disorders other than Alzheimer's disease will be recruited: 1. 160 cases with Frontotemporal dementia (FTD)-related disorders, including behavioral variant of FTD (bvFTD), Progressive nonfluent aphasia (PNFA), semantic dementia (SD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD). 2. 50 cases with subcortical Vascular dementia (VaD). 3. 200 cases with either Parkinson's disease (PD), Parkinson's disease with dementia (PDD), Dementia with Lewy Bodies (DLB), Multiple system atrophy (MSA). FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed. CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group. Motor assessments (Motor-ACT) are performed at baseline and a 2-year follow-up since 7th Oct 2019.
Kezelés: [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau és Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- Illeszkedési kérdések
- Forrás: NCT03174938: ki vehet részt
- Publikációk
- A regiszteradat frissítve
- 2026. április 6.